Candel Therapeutics

Price & Volume

Stats

52W Range	$3.78-$14.30
Market Cap	$249.4M
Shares Short	5M

Financials

Revenue (12 Mos)	$31,000
Revenue Growth (YoY)	0%
Gross Profit (12 Mos)	-$18.2M
Diluted EPS	-$1.74

News

Yahoo Finance • 10 days ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Yahoo Finance • last month

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Yahoo Finance • last month

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Yahoo Finance • 2 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

About

CEO	Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
CFO	Mr. Charles Schoch
Address	117 Kendrick Street, Needham, MA, United States, 02494
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	38